Thus it seems that, even in the presence of plasma protein, gliclazide block is quantitatively sufficient to stimulate insulin secretion and the functional data are in reasonable agreement with the free CSS concentration of drug in the plasma of patients with type 2 diabetes. This evidence concerns the gene INS and type 2 diabetes mellitus.